 SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 GLOBE NEWSWIRE -- 23andMe Holding Co. Nasdaq: ME 23andMe, a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2023 FY2023 second quarter after the market closes on Monday, November 7, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarters financial results and report on business progress. 